Despite recent advances in modern medicine, hundreds of millions of people are affected by acute and chronic diseases with limited or no available treatment options. Kymera is pioneering a game-changing new therapeutic modality with the potential to transform drug discovery and provide breakthrough treatments for previously untreatable diseases.

THE APPROACH

TARGETED PROTEIN DEGRADATION: A TRANSFORMATIVE APPROACH

Kymera’s differentiated drug discovery platform was designed to further advance current targeted protein degradation approaches. Powered by a proprietary predictive modeling capability and a game-changing integrated degradation platform, Kymera is accelerating drug discovery and development with an unmatched ability to identify, target and degrade the most intractable of proteins.

The Technology

Novel Technology

Kymera’s targeted protein degradation platform leverages the body’s ubiquitin proteasome system, which plays an integral role in regulating cellular processes. Using a small molecule-based knockdown strategy, we rationally design and develop heterobifunctional molecules that catalytically recruit specific proteins to E3 ubiquitin ligases, resulting in the protein’s ubiquitination and subsequent degradation.

Differentiated Approach

Until now, progress in the development of protein degradation therapies has been largely driven by empirical approaches, limiting insights and advances in the field. Powered by a proprietary predictive modeling capability and a game-changing integrated degradation platform, Kymera is accelerating drug discovery and development with an unmatched ability to identify, target and degrade the most intractable of proteins.

Leadership Team

Laurent Audoly, Ph.D.
Chief Executive Officer
Read Bio
X
Laurent joined Kymera Therapeutics from Pierre Fabre, where he was the Global Head of R&D and a managing partner at the PF fund for innovation. Laurent started his drug development career at Pfizer, where he led multiple discovery efforts in inflammation and immunology contributing to the identification of Xeljanz®. Subsequently, he held various strategic, leadership and operational roles at MedImmune, Merck, and Pieris, building global collaborations and therapeutic pipeline value across oncology, autoimmunity, respiratory, neuropsychiatry, dermatology, cardiovascular and metabolic diseases, contributing to the launch of multiple products currently on the market. He earned his PhD in Pharmacology from Vanderbilt and was an American Heart Association postdoctoral fellow at Duke University. Laurent has authored >70 patents and papers published in top-tier scientific journals including J Exp Med, Nature Immunology, Nature Medicine, Nature Neuroscience, and PNAS. Laurent is a co-author on more than 70 peer-reviewed publications and patents and has served on various NIH study sections. He serves as a board member and advisor for multiple healthcare organizations worldwide to help accelerate the discovery and advancement of novel therapies for patients and their families.
Nello Mainolfi, Ph.D.
Founder and Chief Technology Officer
Read Bio
X
Before founding Kymera, Nello was head of drug discovery at Raze Therapeutics (an Atlas portfolio company) where he helped develop first in class molecules against novel cancer metabolism targets with implications in both oncology and immuno-metabolism. Nello started his drug discovery career in the global discovery chemistry group at the Novartis Institutes for Biomedical Research, where he contributed and in most cases led teams to the identification of more than 10 compounds that have entered preclinical and clinical development across a series of disease areas. Notably first in class small molecules inhibitors of several complement proteins for inflammation and ocular diseases. While at Novartis he also championed new technologies such as using fragment-based drug discovery as a core strategy to deliver multiple development candidates. Nello has authored >40 papers and patents and has written reviews in the areas of medicinal chemistry and drug discovery. Nello was trained at Imperial College, University of London and The Scripps Research Institute in California.
X
Laurent joined Kymera Therapeutics from Pierre Fabre, where he was the Global Head of R&D and a managing partner at the PF fund for innovation. Laurent started his drug development career at Pfizer, where he led multiple discovery efforts in inflammation and immunology contributing to the identification of Xeljanz®. Subsequently, he held various strategic, leadership and operational roles at MedImmune, Merck, and Pieris, building global collaborations and therapeutic pipeline value across oncology, autoimmunity, respiratory, neuropsychiatry, dermatology, cardiovascular and metabolic diseases, contributing to the launch of multiple products currently on the market. He earned his PhD in Pharmacology from Vanderbilt and was an American Heart Association postdoctoral fellow at Duke University. Laurent has authored >70 patents and papers published in top-tier scientific journals including J Exp Med, Nature Immunology, Nature Medicine, Nature Neuroscience, and PNAS. Laurent is a co-author on more than 70 peer-reviewed publications and patents and has served on various NIH study sections. He serves as a board member and advisor for multiple healthcare organizations worldwide to help accelerate the discovery and advancement of novel therapies for patients and their families.
Before founding Kymera, Nello was head of drug discovery at Raze Therapeutics (an Atlas portfolio company) where he helped develop first in class molecules against novel cancer metabolism targets with implications in both oncology and immuno-metabolism. Nello started his drug discovery career in the global discovery chemistry group at the Novartis Institutes for Biomedical Research, where he contributed and in most cases led teams to the identification of more than 10 compounds that have entered preclinical and clinical development across a series of disease areas. Notably first in class small molecules inhibitors of several complement proteins for inflammation and ocular diseases. While at Novartis he also championed new technologies such as using fragment-based drug discovery as a core strategy to deliver multiple development candidates. Nello has authored >40 papers and patents and has written reviews in the areas of medicinal chemistry and drug discovery. Nello was trained at Imperial College, University of London and The Scripps Research Institute in California.

Board of Directors

Bruce Booth, D.Phil.
Chairman
Read Bio
X
Bruce is a partner at Atlas Venture where he focuses on novel biopharmaceutical products, therapeutic platforms, and innovative biomedical technologies. He is currently chairman AvroBio, mirage Therapeutics, Nimbus Therapeutics, Rodin Therapeutics and Quartet Medicine, and also serves on the boards of Lysosomal Therapeutics, Magenta Therapeutics, Unum Therapeutics, and Zafgen. He previously served on the boards of past Atlas companies Avila (acquired by Celgene), Padlock (acquired by BMS), Prestwick (acquired by Biovail) and Stromedix (acquired by Biogen). Bruce also serves as an advisor in various capacities to UCB, Shire, Pfizer and Takeda, and is on the board of the National Venture Capital Association. As a British Marshall Scholar, Bruce received a D.Phil. in molecule immunology from Oxford University and a B.S. in biochemistry, summa cum laude, from The Pennsylvania State University.
Steve Hall, Ph.D.
Read Bio
X
Steve is a General Partner at Lilly Ventures and has more than 25 years of pharmaceutical experience from both multinational pharmaceutical companies and biotech organizations. Prior to joining Lilly Ventures, Steve was SVP of R&D at Serenex, Inc., where he was also a co-founder. He also has held operational and leadership roles at Eli Lilly, Sphinx Pharmaceuticals, and Bristol-Myers Squibb in the areas of oncology, cardiovascular disease, and lead generation technologies. Steve currently sits on the boards of Cavio Pharma, Esanex, FORMA Therapeutics, Hydra Biosciences, Lysosomal Therapeutics and Nimbus Therapeutics. Steve is the author of more than 40 papers and 60 patents. He received his B.S. in chemistry from Central Michigan University and his Ph.D. in organic chemistry from Massachusetts Institute of Technology
Laurent Audoly, Ph.D.
Read Bio
X
Laurent has led pharma and biotech R&D organizations in the U.S. and EU for more than 20 years, discovering and developing novel medicines, including five approved drugs (both small and large molecule) in inflammation, dermatology, cardiovascular diseases, and oncology. Prior to joining Kymera, Laurent was the head of R&D at Pierre Fabre, an EU-based pharmaceutical company with more than $2.5B in revenues. During his tenure there, he championed the in- and out-licensing of numerous clinical-stage assets and technologies, and directly contributed to IND entries and POC and LCM studies in oncology, dermatology, and neuropsychiatry. He has also held leadership positions at Pfizer, Merck, MedImmune and Pieris. Laurent earned his Ph.D. in pharmacology at Vanderbilt University, and did his post-doctoral training at Duke University where he was awarded a fellowship from the American Heart Association. Laurent is a co-author on more than 70 peer-reviewed publications and patents and has served on various NIH study sections. He serves as a board member and advisor for multiple healthcare organizations worldwide to help accelerate the discovery and advancement of novel therapies for patients and their families.
X
Bruce is a partner at Atlas Venture where he focuses on novel biopharmaceutical products, therapeutic platforms, and innovative biomedical technologies. He is currently chairman AvroBio, mirage Therapeutics, Nimbus Therapeutics, Rodin Therapeutics and Quartet Medicine, and also serves on the boards of Lysosomal Therapeutics, Magenta Therapeutics, Unum Therapeutics, and Zafgen. He previously served on the boards of past Atlas companies Avila (acquired by Celgene), Padlock (acquired by BMS), Prestwick (acquired by Biovail) and Stromedix (acquired by Biogen). Bruce also serves as an advisor in various capacities to UCB, Shire, Pfizer and Takeda, and is on the board of the National Venture Capital Association. As a British Marshall Scholar, Bruce received a D.Phil. in molecule immunology from Oxford University and a B.S. in biochemistry, summa cum laude, from The Pennsylvania State University.
Steve is a General Partner at Lilly Ventures and has more than 25 years of pharmaceutical experience from both multinational pharmaceutical companies and biotech organizations. Prior to joining Lilly Ventures, Steve was SVP of R&D at Serenex, Inc., where he was also a co-founder. He also has held operational and leadership roles at Eli Lilly, Sphinx Pharmaceuticals, and Bristol-Myers Squibb in the areas of oncology, cardiovascular disease, and lead generation technologies. Steve currently sits on the boards of Cavio Pharma, Esanex, FORMA Therapeutics, Hydra Biosciences, Lysosomal Therapeutics and Nimbus Therapeutics. Steve is the author of more than 40 papers and 60 patents. He received his B.S. in chemistry from Central Michigan University and his Ph.D. in organic chemistry from Massachusetts Institute of Technology
Laurent has led pharma and biotech R&D organizations in the U.S. and EU for more than 20 years, discovering and developing novel medicines, including five approved drugs (both small and large molecule) in inflammation, dermatology, cardiovascular diseases, and oncology. Prior to joining Kymera, Laurent was the head of R&D at Pierre Fabre, an EU-based pharmaceutical company with more than $2.5B in revenues. During his tenure there, he championed the in- and out-licensing of numerous clinical-stage assets and technologies, and directly contributed to IND entries and POC and LCM studies in oncology, dermatology, and neuropsychiatry. He has also held leadership positions at Pfizer, Merck, MedImmune and Pieris. Laurent earned his Ph.D. in pharmacology at Vanderbilt University, and did his post-doctoral training at Duke University where he was awarded a fellowship from the American Heart Association. Laurent is a co-author on more than 70 peer-reviewed publications and patents and has served on various NIH study sections. He serves as a board member and advisor for multiple healthcare organizations worldwide to help accelerate the discovery and advancement of novel therapies for patients and their families.

Scientific Advisors

David Spiegel, M.D., Ph.D.
Professor of Chemistry, Yale University
Steven A. Carr, Ph.D.
Senior Director of Proteomics, Broad Institute
Michele Pagano, M.D.
Chair, Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine and Investigator, Howard Hughes Medical Institute
Ning Zheng, Ph.D.
Professor of Pharmacology, University of Washington and Investigator, Howard Hughes Medical Institute

Investors

Contact Us

JOIN US

Kymera is actively recruiting individuals looking to advance a breakthrough new approach to treating disease. Reach out to us at inquiries@kymeratx.com